雄激素治疗的跨性别青少年痤疮的发生率及相关因素：一项回顾性队列研究。
Incidence and Factors Associated With Acne in Transgender Adolescents on Testosterone: A Retrospective Cohort Study.
机构信息
Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia.
Division of Endocrinology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia.
出版信息
Endocr Pract. 2023 May;29(5):353-355. doi: 10.1016/j.eprac.2023.02.002. Epub 2023 Mar 6.
OBJECTIVE
This retrospective cohort study aimed to assess incidence and predictors of acne among transgender adolescents receiving testosterone.
METHODS
We analyzed records of patients aged <18 years, assigned female at birth, seen at Children's Healthcare of Atlanta Pediatric Endocrinology clinic for testosterone initiation between January 1, 2016, and January 1, 2019, with at least 1-year follow-up documented. Bivariable analyses to determine the association of clinical and demographic factors with new acne diagnosis were performed.
RESULTS
Of 60 patients, 46 (77%) did not have baseline acne, but of those 46 patients, 25 (54%) developed acne within 1 year of testosterone initiation. Overall incidence proportion was 70% at 2 years; patients who used progestin prior to or during follow-up were more likely to develop acne than nonusers (92% vs 33%, P <.001).
CONCLUSION
Transgender adolescents starting testosterone, particularly those taking progestin, should be monitored for acne development and treated proactively by hormone providers and dermatologists.
目的
本回顾性队列研究旨在评估接受雄激素治疗的跨性别青少年发生痤疮的发生率和预测因素。
方法
我们分析了 2016 年 1 月 1 日至 2019 年 1 月 1 日期间在亚特兰大儿童医疗保健儿科内分泌诊所因雄激素起始治疗而就诊的年龄<18 岁、出生时被分配为女性且至少有 1 年随访记录的患者的记录。进行了单变量分析以确定临床和人口统计学因素与新发痤疮诊断的关联。
结果
在 60 名患者中，46 名（77%）基线时无痤疮，但在这 46 名患者中，有 25 名（54%）在雄激素起始后 1 年内出现痤疮。2 年内的总体发生率为 70%；与非使用者相比，在随访期间或之前使用孕激素的患者更有可能发生痤疮（92%比 33%，P<0.001）。
结论
开始接受雄激素治疗的跨性别青少年，尤其是那些正在使用孕激素的患者，应接受痤疮发生情况的监测，并由激素提供者和皮肤科医生积极治疗。
Zotero 插件